

For Immediate Release

Company name: DAIICHI SANKYO COMPANY, LIMITED
Representative: Takashi Shoda, President and CEO
(Code no.: 4568, First Section of Tokyo, Osaka and Nagoya Stock Exchanges)
Please address inquiries to Toshiaki Sai, General Manager,
Corporate Communications Department
Telephone: +81-3-6225-1126
<http://www.daiichisankyo.com/>

**Daiichi Sankyo Receives Approval to Manufacture and Market
Rezaltas[®] Combination Tablets to Treat Hypertension**

Tokyo, Japan (January 20, 2010) – Daiichi Sankyo Company, Limited (hereafter; Daiichi Sankyo,) today announced that it has received approval in Japan to manufacture and market Rezaltas[®] combination tablets LD and HD for the treatment of hypertension.

Rezaltas[®] is a combination drug featuring the Daiichi Sankyo-developed olmesartan medoxomil (Olmotec[®]), a high-affinity ARB (angiotensin receptor blocker), and azelnidipine (Calblock[®]), a long-acting CCB (calcium channel blocker) that the company researched and developed with Ube Industries, Ltd. The LD tablet incorporates 10mg of olmesartan medoxomil and 8mg of azelnidipine. The HD tablet employs 20mg and 16 mg, respectively, of these substances.

ARBs and CCBs are often prescribed together in Japan because they address the multiple causes of hypertension in order to reduce blood pressure to target levels. Daiichi Sankyo has combined olmesartan medoxomil, which has proven exceptionally powerful in lowering blood pressure among ARBs, with azelnidipine, a CCB that delivers ongoing decreases in blood pressure while minimizing sympathomimetic hyperactivity. Clinical studies demonstrated that Rezaltas[®] consistently suppresses blood pressure for 24 hours while offering excellent tolerance.

Daiichi Sankyo has a long track record in developing and marketing medications to lower blood pressure, and the company is confident that Rezaltas[®] will contribute significantly to hypertension treatment.

###